Royalty Pharma appoints Dr Bonnie Bassler to its Board of Directors

– USA, NY –  Royalty Pharma today announced the appointment of Dr. Bonnie Bassler, PhD to its Board of Directors, effective immediately.

Dr. Bassler is an accomplished scientist and has served as Chair of the Department of Molecular Biology at Princeton University since 2013.

“Bonnie brings a valuable combination of deep expertise in molecular biology and Board-level experience across academia and the biopharma industry. We look forward to benefiting from her extensive experience and scientific acumen as we advance our strategy as a leading funder of innovation in the biopharma ecosystem,” said Founder and CEO Pablo Legorreta.

He added: “As Royalty Pharma begins the next phase of its development as a public company, we are delighted to strengthen our Board with the appointment of Dr. Bassler.”

About Dr Bonnie Bassler

Dr. Bassler holds a BS in Biochemistry from the University of California-Davis and a PhD in Biochemistry from the Johns Hopkins University. In addition to her longstanding leadership roles at Princeton University, Dr. Bassler is serving or has served on the boards of several biopharmaceutical companies, including Sanofi, Kaleido Biosciences and Regeneron Pharmaceuticals, and as a Trustee of the Alfred P. Sloan Foundation. Dr. Bassler has also served as a Board member of the American Association for the Advancement of Science and as a member of the National Science Board.

About Royalty Pharma

Founded in 1996, Royalty Pharma is a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates.

For more information: http://www.royaltypharma.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>